EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Studies of the pharmacokinetics and toxicology of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) in vivo; and synthesis and antiviral evaluations of 2',3'-dideoxy-beta-L-5-azacytidine



Studies of the pharmacokinetics and toxicology of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) in vivo; and synthesis and antiviral evaluations of 2',3'-dideoxy-beta-L-5-azacytidine



Nucleosides and Nucleotides 14(3-5): 619-625



The pharmacokinetics and toxicology of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) in mice was investigated.

(PDF emailed within 1 workday: $29.90)

Accession: 009472687

Download citation: RISBibTeXText



Related references

Studies of the pharmacokinetics and toxicology of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine in vivo; and synthesis and antiviral evaluations of 2,3-dideoxy-beta-L-5-azacytidine. Nucleosides & Nucleotides 14(3-5): 619-625, 1995

Studies of the Pharmacokinetics and Toxicology of 2',3'-Dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2',3'-Dideoxy-β-L-cytidine (β-L-ddC) In Vivo; and Synthesis and Antiviral Evaluations of 2',3'-Dideoxy-β-L-5-azacytidine. Nucleosides Nucleotides & Nucleic Acids 14(3): 619-625, 1995

Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochemical Pharmacology 47(2): 171-174, 1994

Immunomodulatory and antiviral activities of 2',3'-dideoxy-beta-L-cytidine and 2',3'-dideoxy-beta-L-5-fluorocytidine. Immunopharmacology and Immunotoxicology 17(1): 17-32, 1995

Importance of the urinary excretion in the total elimination of sc 4453 3 beta 5 beta 12 beta 14 beta 17 beta 12 14 di hydroxy 17 4 pyridazinylandrostan 3 yl o 2 6 dideoxy beta d ribohexopyranosyl 1 4 o 2 6 dideoxy beta d ribohexopyranosyl 1 4 2 6 dideoxy beta d ribo hexo pyranoside in the guinea pig. Journal de Pharmacologie (Paris) 15(2): 199-208, 1984

Antiviral activity of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine against hepatitis B virus and human immunodeficiency virus type 1 in-vitro. Biochemical Pharmacology 47(2): 171-174, 1994

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Synthesis of methyl 2 6 dideoxy beta d arabino 3 6 dideoxy beta d ribo and 4 6 dideoxy beta d xylohexopyranosides. Khimiya Prirodnykh Soedinenii (6): 741-743, 1991

Pre-clinical pharmacology of beta-L-2,3-dideoxy-5-fluorocytidine and its prodrug bis- SATE-beta-L-2,3-dideoxy-5-fluorocytidine monophosphate. Antiviral Research 37(3): A64, March, 1998

Design and synthesis of 2,3-dideoxy-2,3-didehydro-beta-L-cytidine and 2,3-dideoxy-2,3-didehydro-beta-L-5-fluorocytidine , two exceptionally potent inhibitors of human hepatitis B virus and potent inhibitors of human immunodeficiency virus in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Coordination features of difunctionalized beta-cyclodextrins with carnosine: ESI-MS and spectroscopic investigations on 6A,6D-di-(beta-alanyl-L-histidine)-6A,6D-dideoxy-beta-cyclodextrin and 6A,6C-di-(beta-alanyl-L-histidine)-6A,6C-dideoxy-beta-cyclodextrin and their copper(II) complexes. Journal of Inorganic Biochemistry 98(2): 254-265, 2004

Studies on sialic acids. Part XXII. Synthesis of 6-O-(5-acetamido-3,5-dideoxy-D-glycero-.ALPHA.- and -.BETA.-D-galacto-nonuropyranosonic acid)-(2.RAR.6)-O-.BETA.-D-galactopyranosyl-(1.RAR.4)-1-(5-cholesten-3.BETA.-yloxy)-.BETA.-D-glucopyranose. Chemical & Pharmaceutical Bulletin 38(8): 2083-2087, 1990

Coordination features of difunctionalized beta-cyclodextrins with carnosine ESI-MS and spectroscopic investigations on 6A,6D-di- -6A,6D-dideoxy-beta-cyclodextrin and 6A,6C-di- -6A,6C-dideoxy-beta-cyclodextrin and their copper complexes. Journal of Inorganic Biochemistry 98(2): 254-265, February, 2004

Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrobial Agents and ChemoTherapy 43(2): 381-384, 1999

Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys. Antimicrobial Agents and ChemoTherapy 49(7): 2589-2597, 2005